Sorrento Therapeutics rejects unsolicited all-cash offerChristian Fernsby ▼ | November 25, 2019
Sorrento Therapeutics said it had rejected an unsolicited buyout offer from two biopharmaceutical companies.
Acquisition offer Offers were between $3.00 and $5.00 per share in cash
Topics: Sorrento Therapeutics
"Accordingly, the board unanimously rejected the proposal," it said.
Sorrento said it is in active late-stage licensing and collaboration discussions with "leading" biopharmaceutical companies for its immuno-oncology products. It said that these pending transactions alone "represent potential short- and long-term value creation significantly exceeding the current all cash proposal".
Chairman and chief executive officer Dr. Henry Ji said: "The Sorrento board of directors and management team are committed to serving the best interests of the company and Sorrento stockholders, and are confident in the company's strategic direction and our ability to implement it."
The group said there is no guarantee that the unsolicited buyout proposal will lead to a recommended firm offer or that it will complete any pending licensing or collaboration transaction for its immunotherapy platforms. ■